• Ruxolitinib (INCB018424) in JAK-STAT Pathway and Myelofibros

  2026-06-17

  Ruxolitinib (INCB018424) transforms myeloproliferative disorder research with selective, potent JAK1/2 inhibition and robust compatibility with advanced immunoprofiling workflows. This guide details protocol enhancements, real-world troubleshooting, and cross-study insights for achieving reproducible, high-resolution results in JAK-STAT signaling and myelofibrosis research.

• Halazone and Oxidants: Modulating Sodium Channel Inactivatio

  2026-06-17

  This article examines the mechanistic findings from a classic study on the effects of Halazone and related oxidants on sodium current inactivation in frog myelinated nerve fibers. The work clarifies the molecular targets of Halazone in neurophysiology and highlights its value as a probe for membrane biophysics and sodium channel modulation.

• CB-839 (Telaglenastat): Applied Workflows in Cancer Metaboli

  2026-06-16

  CB-839 (Telaglenastat) offers researchers a selective and reversible approach to dissecting glutamine metabolism in cancer models. This article delivers workflow optimizations, troubleshooting strategies, and actionable insights, enabling robust experimental outcomes in preclinical cancer metabolism research.

• APOC1 Drives PTC Progression: Cyclopamine’s Synergistic Effe

  2026-06-16

  This study identifies Apolipoprotein C1 (APOC1) as a critical driver of papillary thyroid carcinoma (PTC) progression and immune evasion, using integrated bioinformatic and experimental approaches. It further demonstrates that cyclopamine, a Hedgehog signaling inhibitor, synergistically amplifies apoptosis and growth inhibition in APOC1-high PTC models, suggesting a promising therapeutic axis for targeted intervention.

• Bradykinin: Redefining Endothelial Vasodilation for Translat

  2026-06-15

  This thought-leadership article provides advanced insight into Bradykinin’s mechanisms as an endothelium-dependent vasodilator while equipping translational researchers with strategic guidance for leveraging this peptide in cardiovascular, pain, and inflammation research. Bridging recent mechanistic findings with practical protocol recommendations, the article critically evaluates the evolving competitive landscape and underscores APExBIO’s commitment to research reproducibility. Through evidence-based narrative and scenario-driven recommendations, it empowers labs to maximize Bradykinin’s translational value in preclinical and applied models.

• Sodium Phosphate Dibasic: Buffering Excellence for Translati

  2026-06-15

  This thought-leadership article explores the mechanistic and strategic role of sodium phosphate dibasic (Na2HPO4) as a cornerstone buffer in aquatic toxicity and molecular biology assays. Drawing on recent ecotoxicological findings, authoritative workflow guides, and APExBIO’s competitive product intelligence, it delivers practical guidance for translational researchers seeking reproducibility, regulatory alignment, and cross-domain impact.

• Staurosporine as a Broad-Spectrum Kinase Inhibitor in Tumor

  2026-06-14

  Explore Staurosporine's role as a broad-spectrum serine/threonine protein kinase inhibitor in dissecting tumor microenvironment dynamics, apoptosis, and angiogenesis. This deep-dive article provides new insights for cancer research and advanced protocol optimization.

• Prevotella copri, IPyA Depletion, and Breast Cancer Progress

  2026-06-13

  This study elucidates how enrichment of Prevotella copri in the gut microbiota promotes breast cancer progression by depleting host indole-3-pyruvic acid (IPyA), thereby inactivating AMPK signaling via UHRF1-mediated regulation. These mechanistic insights highlight a direct microbial-metabolic-epigenetic axis in cancer biology, opening new avenues for metabolic and microbiome-targeted research.

• Diclofenac in Human iPSC-Intestinal Organoids: Protocols, Pi

  2026-06-12

  Explore the advanced use of Diclofenac, a non-selective COX inhibitor, in human iPSC-derived intestinal organoid research. This article reveals overlooked protocol optimizations, real-world assay limitations, and the latest innovations for inflammation and pharmacokinetic modeling—bridging gaps left by prior reviews.

• PRMT5-Regulated Splicing Links Epitranscriptome to Glutamine

  2026-06-12

  This study reveals that MYCN-amplified neuroblastoma exhibits a unique vulnerability to PRMT5 inhibition, resulting in coordinated disruptions in RNA splicing, epitranscriptomic regulation, and glutamine metabolism. The findings position metabolic and splicing pathways as convergent therapeutic targets and inform experimental strategies for cancer metabolism research.

• Thapsigargin (SKU B6614): Reliable SERCA Pump Inhibitor for

  2026-06-11

  This article delivers scenario-driven guidance for biomedical researchers utilizing Thapsigargin (SKU B6614) as a gold-standard SERCA pump inhibitor. We address common experimental challenges in apoptosis, calcium signaling, and endoplasmic reticulum stress assays, highlighting APExBIO’s Thapsigargin for its reproducibility and validated performance.

• Applied Workflows with EdU Flow Cytometry Assay Kits (Cy3)

  2026-06-11

  The EdU Flow Cytometry Assay Kits (Cy3) unlock rapid, denaturation-free detection of S-phase DNA synthesis, enabling high-fidelity cell proliferation and genotoxicity studies. This guide details practical workflows, advanced use-cases in immune and cancer research, and actionable troubleshooting, bridging the kit’s molecular innovations to robust experimental outcomes.

• Indole-3-pyruvic Acid: Mechanisms and Benchmarks in Immunity

  2026-06-10

  Indole-3-pyruvic acid (IPA) is a central tryptophan metabolite with pivotal roles in plant hormone biosynthesis and mammalian immune modulation. Evidence demonstrates IPA’s ability to regulate auxin pathways in plants and to alleviate rheumatoid arthritis in animal models via the aryl hydrocarbon receptor (AhR). This dossier summarizes mechanisms, protocol parameters, and translational benchmarks for IPA research.

• Toremifene Citrate: Mechanistic Insights in Breast Cancer Th

  2026-06-10

  The reference study establishes Toremifene Citrate as a clinically validated oral selective estrogen receptor modulator (SERM) for hormone receptor-positive breast cancer, with mechanistic parallels to tamoxifen. Its nuanced receptor modulation, metabolism, and unique adverse event profile provide key considerations for translational and laboratory research.

• HyperPFU™ high-fidelity DNA polymerase: Technical Applicatio

  2026-06-09

  HyperPFU™ high-fidelity DNA polymerase provides robust, accurate PCR amplification for long or GC-rich DNA templates that challenge standard enzymes. It is optimized for workflows needing blunt-ended, high-fidelity products, but should not be used for protocols requiring 3'-A overhangs or sticky-end ligations.

16402 records 1/1094 page Next 12345 下5页 Last page